BioSpace News Archive

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three months ending March 31, 2021 and provided a corporate update.

Algernon Pharmaceuticals Inc. announces it has received positive feedback from the U.S. Food and Drug Administration regarding its plans to investigate AP-188, a known psychedelic compound that is part of the tryptamine family, as an adjunct to physical therapy in the rehabilitation of stroke.

Milestone Pharmaceuticals Inc. announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China.

AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, announced the activation of four additional clinical trial sites in Canada and the United States for its pivotal REACH-CDM study evaluating the efficacy and safety of the investigational therapy AMO-02 in the treatment of congenital myotonic dystrophy.

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the U.S. and European full market launch of the OSCAR PRO ™ Ultrasonic Arthroplasty Revision System.

Veeva Systems announced a strategic partnership with Oncopeptides to support the launch of the global biotech’s first commercial product.

New Appointments Bring Expertise and Proven Leadership to Support Asset-Centric R&D Model and Portfolio Advancement

Applied UV, Inc., an infection control technology company that applies the power of narrow-range ultraviolet light for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced first quarter results for 2021.

StageZero Life Sciences, Ltd., a specialist in PCR testing dedicated to the early detection of multiple diseases through whole blood, announced its first-quarter financial results for the three months ended March 31, 2021, and provided an update on its business progress.

Paratek Pharmaceuticals, Inc. today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2021.